<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736826</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2012/SB-01</org_study_id>
    <secondary_id>2014-A01120-47</secondary_id>
    <nct_id>NCT01736826</nct_id>
  </id_info>
  <brief_title>Free DNA and Nucleosome Concentrations in Pathological Pregnancies</brief_title>
  <official_title>Comparative Study of Plasma Free DNA and Nucleosome Concentrations: Pathological Versus Normal Pregnancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate that plasma concentrations of
      nucleosomes and free DNA differ between three groups:

        1. pregnant patients with complications typical of placental insufficiency or venous
           thrombosis (group P),

        2. healthy women (Group T1) and

        3. healthy pregnant women (Group T2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our secondary objectives include the following:

        1. To describe, in 15 healthy, non-pregnant women changes in plasma concentrations of
           nucleosomes and free DNA over 3 months.

        2. To describe, in 15 pregnant women (without complications), changes in plasma
           concentrations of nucleosomes and free DNA over the last 7 months of pregnancy

        3. To show that plasma concentrations of nucleosomes and free DNA, in patients with
           complicated pregnancies differ according to the nature of the complication

        4. To show that a relationship exists between the concentrations of nucleosomes, free DNA,
           and total granulocyte microparticles (and trophoblast particles for pregnant women)

        5. To evaluate the relationship between nucleosome concentrations, free DNA concentrations
           and circulating leukocyte populations

        6. To evaluate the relationship between nucleosome concentrations, free DNA concentrations
           and hemostasis markers

        7. To describe changes in hemostasis markers throughout pregnancy

        8. To evaluate the relationship between nucleosome concentrations, free DNA concentrations
           and the angiogenic marker CD146

        9. To add to the Nîmes University Hospital biological collections.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>Base line (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>Base line (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>baseline (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>1 month</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>2 months</time_frame>
    <description>For group T1x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear neutrophils(g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (fL)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin (pg/GR)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear eosinophils (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polynuclear basophils (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers (ng/ml)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin monomers (ng/ml)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trophoblast microparticles (%)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic marker CD146 (ng/ml)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of nucleosomes (AU)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma concentration of free DNA (ng/ml)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>Base line (day 0)</time_frame>
    <description>For group P, baseline occurs within the 30 days preceding birth. For group T1, baseline = time of inclusion. For group T2, baseline occurs within the 30 days preceding birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-1 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-2 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-3 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-4 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-5 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (g/l)</measure>
    <time_frame>-6 months</time_frame>
    <description>For group T2x only.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Pregnancy</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Hypertension, Pregnancy-Induced</condition>
  <condition>Eclampsia</condition>
  <condition>HELLP Syndrome</condition>
  <condition>Pre-Eclampsia</condition>
  <condition>Fetal Death</condition>
  <condition>Placental Insufficiency</condition>
  <arm_group>
    <arm_group_label>Group P: pregnancy w/complications</arm_group_label>
    <description>The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism).
100 patients will be included.
Interventions to be administered: Bloodwork, baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T1: Healthy volunteers</arm_group_label>
    <description>Healthy volunteers with no history of chronic or neoplastic disease.
30 healthy volunteers will be included.
Interventions to be administered: Bloodwork, baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T2: Pregnancy, no complications</arm_group_label>
    <description>Pregnant patients with no identifiable pregnancy complications, and no history of chronic or neoplastic disease.
50 pregnant volunteers will be included.
Interventions to be administered: Bloodwork, baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T1x: 15 Healthy volunteers</arm_group_label>
    <description>15 Healthy volunteers selected from group T1 (the first 15). These patients will have 2 additional months of follow up.
Interventions to be administered: Blood work, Months 1 &amp; 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T2x: 15 Pregnancy, no complications</arm_group_label>
    <description>15 patients selected from group T2 (the first 15); these patients will have 7 months of follow up during pregnancy.
Interventions to be administered: Bloodwork, Months -1 to -6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bloodwork, baseline</intervention_name>
    <description>36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.</description>
    <arm_group_label>Group P: pregnancy w/complications</arm_group_label>
    <arm_group_label>Group T1: Healthy volunteers</arm_group_label>
    <arm_group_label>Group T2: Pregnancy, no complications</arm_group_label>
    <arm_group_label>Group T1x: 15 Healthy volunteers</arm_group_label>
    <arm_group_label>Group T2x: 15 Pregnancy, no complications</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood work, Months 1 &amp; 2</intervention_name>
    <description>36 ml of blood are drawn at 1 &amp; 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.</description>
    <arm_group_label>Group T1x: 15 Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bloodwork, Months -1 to -6</intervention_name>
    <description>36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.</description>
    <arm_group_label>Group T2x: 15 Pregnancy, no complications</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At each visit a total of 36 ml of blood will be drawn (5 x EDTA tube = 5 x 4.5ml; 2 x CTAD
      tube = 2 x 4.5 ml and 1 dry tube = 4.5 ml).

      Tubes will be rapidly conditioned and samples stored at -80°C. After analysis, remaining
      samples will be stored in the Nîmes University Hospital Biological Collections.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes three groups:

        Group P: 100 pregnant women with complications typical of placental vascular disease or
        venous thromboembolism.

        Group T1: 30 non-pregnant, healthy volunteers

          -  The first 15 patients from group T1 will form group T1x. The latter group has two
             months of additional follow up.

        Group T2: 50 pregnant, healthy volunteers

          -  The first 15 patients from group T2 will form group T2x. The latter group has 7 months
             of follow-up during pregnancy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for all patients:

          -  The patient must have given her informed and signed consent

          -  The patient must be insured or beneficiary of a health insurance plan

        Inclusion Criteria for patients in group P:

          -  The patient is pregnant and has complications typical of placental vascular disease
             (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal
             death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism)

        Inclusion Criteria for patients in group T1:

          -  The patient is available for 3 months of follow-up

          -  The patient is a non-pregnant healthy volunteer

          -  No identifiable chronic pathologies

          -  No history of neoplastic disease

          -  No history of chronic infectious disease

          -  No acute disease (such as benign infection), now or within the past two weeks

        Inclusion Criteria for patients in group T2:

          -  The patient is available for 7 months of follow-up

          -  The patient is pregnant, with no identifiable pregnancy complications

          -  No identifiable chronic pathologies

          -  No history of neoplastic disease

          -  No history of chronic infectious disease

          -  No acute disease (such as benign infection), now or within the past two weeks

        Exclusion Criteria for all patients:

          -  The patient is participating in another study (with the exception of the following
             studies: PAPILLO-PMA (2013-A00538-37), ElastoMAP (2013-A01148-37), ElastoDéclenche
             (2014-A00828-39), LXRs (2009-A00968-49), Bakri (2013-A00914-41), OASIS 2
             (2013-A00022-43)).

          -  The patient is in an exclusion period determined by a previous study

          -  The patient is under judicial protection, under tutorship or curatorship

          -  The patient refuses to sign the consent

          -  It is impossible to correctly inform the patient

          -  The patient cannot read French

          -  The patient is receiving hormonal ovarian stimulation in the context of medically
             assisted procreation

          -  Impossible to perform venipuncture under good conditions

          -  New complication or pathology during the study (except for pregnancy complications in
             group P)

        Exclusion Criteria for group P:

          -  Twin or multiple pregnancy

          -  The patient is participating in another study (with the exception of those mentioned
             in the exclusion criteria for all patients and the DG Postpartum study
             (2013-A00277-38)

        Exclusion Criteria for group T1:

          -  The patient is pregnant

          -  The patient is breast feeding

          -  The patient has given birth within the last 3 months

          -  Known history of chronic disease

          -  History of treated neoplastic disease

          -  Acute disease within the past two weeks (includes benign disease)

        Exclusion Criteria for group T2:

          -  Pregnancy with complications

          -  Known history of chronic disease

          -  History of treated neoplastic disease

          -  Acute disease within the past two weeks (includes benign disease)

          -  Twin or multiple pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Bouvier, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eve Mousty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>November 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plasma nucleosome concentration</keyword>
  <keyword>plasma free DNA concentration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>HELLP Syndrome</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Placental Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

